CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,501 enrolled
Drug / intervention
Percutaneous coronary intervention (Promus PREMIER)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02240810
NCT02240810N/ACompleted

PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)

Boston Scientific Corporation·observational·Posted Sep 16, 2014·Updated May 15, 2019

In Brief

An observational study evaluating Percutaneous coronary intervention (Promus PREMIER) for Atherosclerosis and Coronary Artery Disease. Completed, enrolled 1,501 participants across 52 sites.

Detailed Summary

To compile acute procedural performance and clinical outcomes data for the Promus PREMIER everolimus-eluting coronary stent system in understudied/underserved patient populations including women and minorities.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 16, 2014
Enrollment StartOct 1, 2014
Primary CompletionSep 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.8 years ago

Interventions

Percutaneous coronary intervention (Promus PREMIER)device

Interventional coronary artery stenting with Promus PREMIER study stent.